Lexicon Pharmaceuticals announces positive topline clinical data for LX9211
Lexicon announced positive topline results from its Phase 1a study of LX9211, a potent oral small molecule inhibitor of adaptor associated kinase 1, or AAK1, in development for the treatment of neuropathic pain. December 18, 2018